The trial involved three people with melanomas who received the RNA-load nanoparticles intravenously four times, for 30 minutes, over three weeks. At the end of that time, samples taken from the melanomas showed both the presence of the RNA, and a reduction in tumor gene expression.
This technology still has a long way to go before it becomes a routine medical treatment. However, by targeting the epigenome, the expression of genes, as opposed to DNA itself, it has much more practical potential than genetic therapy. Plus, since RNAi can work against any transcription, RNAi nanobots could potentially disable both DNA viruses, like smallox, and RNA viruses, like SARS.
Thursday, March 25, 2010